Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 62
Filter
1.
Mol Pharm ; 16(5): 2048-2059, 2019 05 06.
Article in English | MEDLINE | ID: mdl-30965005

ABSTRACT

The purpose of this study was to assess whether cationic nanoliposomes could address tumor vaccines to dendritic cells in the lungs in vivo. Nanoliposomes were prepared using a cationic lipid, dimethylaminoethanecarbamoyl-cholesterol (DC-cholesterol) or dioleoyltrimethylammoniumpropane (DOTAP), and dipalmitoylphosphatidylcholine (DPPC), the most abundant phospholipid in lung surfactant. The liposomes presented a size below 175 nm and they effectively entrapped tumor antigens, an oligodeoxynucletotide containing CpG motifs (CpG) and the fluorescent dye calcein used as a tracer. Although the liposomes could permanently entrap a large fraction of the actives, they could not sustain their release in vitro. Liposomes made of DOTAP were safe to respiratory cells in vitro, while liposomes composed of DC-cholesterol were cytotoxic. DOTAP nanoliposomes were mainly taken up by alveolar macrophages following delivery to the lungs in mice. Few dendritic cells took up the liposomes, and interstitial macrophages did not take up liposomal calcein more than they took up soluble calcein. Stimulation of the innate immune system using liposomal CpG strongly enhanced uptake of calcein liposomes by all phagocytes in the lungs. Although a small percentage of dendritic cells took up the nanoliposomes, alveolar macrophages represented a major barrier to dendritic cell access in the lungs.


Subject(s)
CpG Islands/immunology , Dendritic Cells/drug effects , Drug Delivery Systems/methods , Liposomes/pharmacokinetics , Lung/cytology , Lung/drug effects , Macrophages, Alveolar/drug effects , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Adjuvants, Immunologic/therapeutic use , Animals , Cancer Vaccines/therapeutic use , Cell Line, Tumor , Cell Survival/drug effects , Cholesterol/analogs & derivatives , Cholesterol/pharmacokinetics , Fatty Acids, Monounsaturated/pharmacokinetics , Female , Fluoresceins/pharmacokinetics , Fluorescent Dyes/pharmacokinetics , Lipopeptides , Liposomes/chemical synthesis , Lung Neoplasms/pathology , Lung Neoplasms/therapy , MART-1 Antigen/pharmacology , Mice , Nanoparticles/chemistry , Quaternary Ammonium Compounds/pharmacokinetics , Tissue Distribution , gp100 Melanoma Antigen/pharmacology
2.
Drug Deliv ; 22(5): 598-607, 2015.
Article in English | MEDLINE | ID: mdl-24524364

ABSTRACT

When polyethylene glycol (PEG)ylated liposomes were repeatedly injected into the same animal, the second dose of liposomes would rapidly clear from the bloodstream and enhance accumulation in the liver and spleen, and this phenomenon is called "accelerated blood clearance (ABC)". There are many factors known to influence ABC phenomenon, in this study, we mainly focused on the effects of different phospholipids (PL) types and animal models. The effects of PL types on ABC phenomenon were examined by repeating injection of PEGylated liposomes prepared by five different types of PL (hydrogenated soy phosphatidylcholine, egg sphingomyelin, soybean phosphatidycholin, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and egg phosphatidycholin) in rats. Dramatically, repeated injection of different types of PL could induce ABC phenomenon altogether. Both t1/2 and AUC of experimental group (EG) were lower significantly than those of control group (CG). Our results also showed that the liver accumulation of second dose increased significantly (p < 0.01) in all EG as compared that of CG. Interestingly, ABC phenomenon of liposomes prepared by unsaturated PL was more obvious than that of saturated PL. All the first dose could induce the antibody (anti-PEG IgM) level increasing significantly (p < 0.01). For different animal models, we found that after repeated injection of PEGylated liposomes, rats, mice, rabbits and guinea pigs could produce ABC phenomenon. Various PL types and animal models could all produce the ABC phenomenon. However, their extent of accelerated clearance differed. ABC phenomenon is possibly a ubiquitous immune phenomenon in life.


Subject(s)
Liposomes/pharmacokinetics , Liver/metabolism , Phospholipids/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , 1,2-Dipalmitoylphosphatidylcholine/analogs & derivatives , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Animals , Antibodies/immunology , Guinea Pigs , Immunoglobulin M/immunology , Metabolic Clearance Rate , Mice , Models, Animal , Ovum , Phosphatidylcholines/pharmacokinetics , Rabbits , Rats , Glycine max , Sphingomyelins/pharmacokinetics
3.
PLoS One ; 9(12): e93612, 2014.
Article in English | MEDLINE | ID: mdl-25551219

ABSTRACT

BACKGROUND: Bacterial pneumonia in newborns often leads to surfactant deficiency or dysfunction, as surfactant is inactivated or its production/turnover impaired. No data are available in vivo in humans on the mechanism of surfactant depletion in neonatal pneumonia. We studied the kinetics of surfactant's major component, disaturated-phosphatidylcholine (DSPC), in neonatal pneumonia, and we compared our findings with those obtained from control newborn lungs. METHODS: We studied thirty-one term or near-term newborns (gestational age 39.7±1.7 weeks, birth weight 3185±529 g) requiring mechanical ventilation. Fifteen newborns had pneumonia, while 16 newborns were on mechanical ventilation but had no lung disease. Infants received an intratracheal dose of 13C labeled dipalmitoyl-phosphatidylcholine at the study start. We measured the amount and the isotopic enrichment of DSPC-palmitate from serial tracheal aspirates by gas chromatography and gas chromatography-mass spectrometry, respectively, and we calculated the DSPC half-life (HL) and pool size (PS) from the isotopic enrichment curves of surfactant DSPC-palmitate. RESULTS: The mean DSPC amount obtained from all tracheal aspirates did not differ between the two groups. DSPC HL was 12.7 (6.5-20.2) h and 25.6 (17.9-60.6) h in infants with pneumonia compared with control infants (p = 0.003). DSPC PS was 14.1 (6.6-30.9) mg/kg in infants with pneumonia and 34.1 (25.6-65.0) mg/kg in controls, p = 0.042. Myeloperoxidase (MPO) activity, as a marker of lung inflammation, was 1322 (531-2821) mU/ml of Epithelial Lining Fluid (ELF) and 371(174-1080) mU/ml ELF in infants with pneumonia and in controls, p = 0.047. In infants with pneumonia, DSPC PS and HL significantly and inversely correlated with mean Oxygenation Index (OI) during the study (DSPC PS vs. OI R = -0.710, p = 0.004 and HL vs. OI R = -0.525, p = 0.044, respectively). CONCLUSIONS: We demonstrated for the first time in vivo in humans that DSPC HL and PS were markedly impaired in neonatal pneumonia and that they inversely correlated with the degree of respiratory failure.


Subject(s)
Phosphatidylcholines/metabolism , Pneumonia/metabolism , 1,2-Dipalmitoylphosphatidylcholine/administration & dosage , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Case-Control Studies , Diagnostic Uses of Chemicals , Female , Gestational Age , Half-Life , Humans , Infant, Newborn , Infant, Premature , Lung/metabolism , Male , Peroxidase/metabolism , Pneumonia/therapy , Prospective Studies , Respiration, Artificial
4.
ChemMedChem ; 6(4): 678-85, 2011 Apr 04.
Article in English | MEDLINE | ID: mdl-21370475

ABSTRACT

The structure and the in vitro behavior of liposomes filled with the cytotoxic drug doxorubicin (Doxo) and functionalized on the external surface with a branched moiety containing four copies of the 8-13 neurotensin (NT) peptide is reported. The new functionalized liposomes, DOPC-NT4Lys(C18)2, are obtained by co-aggregation of the DOPC phospholipid with a new synthetic amphiphilic molecule, NT4 Lys(C18)2, which contains a lysine scaffold derivatized with a lipophilic moiety and a tetrabranched hydrophilic peptide, NT8-13, a neurotensin peptide fragment well known for its ability to mimic the neurotensin peptide in receptor binding ability. Dynamic light scattering measurements indicate a value for the hydrodynamic radius (RH) of 88.3±4.4 nm. The selective internalization and cytotoxicity of DOPC-NT4 Lys(C18)2 liposomes containing Doxo, as compared to pure DOPC liposomes, were tested in HT29 human colon adenocarcinoma and TE671 human rhabdomyosarcoma cells, both of which express neurotensin receptors. Peptide-functionalized liposomes show a clear advantage in comparison to pure DOPC liposomes with regard to drug internalization in both HT29 and TE671 tumor cells: FACS analysis indicates an increase in fluorescence signal of the NT4-liposomes, compared to the DOPC pure analogues, in both cell lines; cytotoxicity of DOPC-NT4 Lys(C18)2-Doxo liposomes is increased four-fold with respect to DOPC-Doxo liposomes in both HT29 and TE671 cell lines. These effects could to be ascribed to the higher rate of internalization for DOPC-NT4 Lys(C18)2-Doxo liposomes, due to stronger binding driven by a lower dissociation constant of the NT4-liposomes that bind the membrane onto a specific protein, in contrast to DOPC liposomes, which approach the plasma membrane unselectively.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Delivery Systems , Liposomes/pharmacology , Neurotensin , Peptide Fragments , 1,2-Dipalmitoylphosphatidylcholine/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , 1,2-Dipalmitoylphosphatidylcholine/pharmacology , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Humans , Hydrodynamics , Liposomes/chemistry , Liposomes/pharmacokinetics , Lysine/chemistry , Lysine/metabolism , Neurotensin/chemistry , Neurotensin/pharmacokinetics , Peptide Fragments/chemistry , Peptide Fragments/pharmacokinetics , Rhabdomyosarcoma/metabolism , Rhabdomyosarcoma/pathology , Tumor Cells, Cultured
5.
J Biomed Mater Res A ; 91(1): 140-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-18770522

ABSTRACT

This study reports the effect of liposome particle size at the nanoscale and bilayer deformability on the permeation through MatTek human skin equivalents and provides a comparative quantitative measure through calculation of diffusion coefficients. Exploring DOPC and DPPC fluorescent liposomes, our results demonstrate the faster diffusion of 50 nm liposomes compared with 100 and 200 nm liposomes when the lipid bilayer remains the same. Diffusion kinetics of the 50 nm particles appear not to depend on the rigidity of the lipid layer, whereas diffusion of particles larger than 100 nm is significantly affected by the rigidity of the bilayer, and DOPC liposomes diffuse faster than their DDPC equivalents. Our results suggest that liposomes composed of a rigid bilayer can be expected to remain intact after passing through the stratum corneum.


Subject(s)
Liposomes/chemistry , Liposomes/pharmacokinetics , Particle Size , Skin/metabolism , 1,2-Dipalmitoylphosphatidylcholine/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Diffusion , Humans , Phosphatidylcholines/chemistry , Phosphatidylcholines/pharmacokinetics
6.
Am J Physiol Lung Cell Mol Physiol ; 293(4): L1053-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17616648

ABSTRACT

Components of surfactant act as opsonins and enhance phagocytosis of bacteria; whether this process occurs with atmospheric fine particles has not been shown. We have studied the interactions of fine particles (urban PM(2.5)) and surfactant removed from normal human lungs by lavage, using a surface analysis technique. The aim was to identify which of the chemical components of brochoalveolar lavage (BAL) deposit on the surfaces of urban PM(2.5). Deposition of surfactant components on urban PM(2.5) surfaces was reported in previous studies, but molecular identification and relative quantification was not possible using simple data analysis. In this study, we were able to identify adsorbed components by applying an appropriate statistical technique, factor analysis. In this study, the most strongly associated mass fragment on PM(2.5) surfaces exposed to BAL (and undetected on both untreated samples and saline controls) was di-palmitoyl-phosphatidylcholine, a component of lung surfactant. Amino acids were also strongly associated with BAL-exposed PM(2.5) surfaces and not other sample types. Thirteen mass fragments were identified, diagnostic of the amino acids alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, and valine. This study provides evidence that lung surfactant and amino acids related to opsonin proteins adsorb to nonbiological particle surfaces exposed to human lung lining fluid. Disruption of normal surfactant function, both physical and immunological, is possible but unproven. Further work on this PM-opsonin interaction is recommended.


Subject(s)
Amino Acids/pharmacokinetics , Bronchoalveolar Lavage Fluid/chemistry , Lung/metabolism , Particulate Matter/chemistry , Pulmonary Surfactants/pharmacokinetics , Urban Population , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Adsorption , Amino Acids/chemistry , Factor Analysis, Statistical , Humans , Opsonin Proteins/chemistry , Particle Size , Pulmonary Surfactants/chemistry
7.
Respir Res ; 8: 13, 2007 Feb 21.
Article in English | MEDLINE | ID: mdl-17313681

ABSTRACT

BACKGROUND: In patients with acute respiratory distress syndrome (ARDS), it is well known that only part of the lungs is aerated and surfactant function is impaired, but the extent of lung damage and changes in surfactant turnover remain unclear. The objective of the study was to evaluate surfactant disaturated-phosphatidylcholine turnover in patients with ARDS using stable isotopes. METHODS: We studied 12 patients with ARDS and 7 subjects with normal lungs. After the tracheal instillation of a trace dose of 13C-dipalmitoyl-phosphatidylcholine, we measured the 13C enrichment over time of palmitate residues of disaturated-phosphatidylcholine isolated from tracheal aspirates. Data were interpreted using a model with two compartments, alveoli and lung tissue, and kinetic parameters were derived assuming that, in controls, alveolar macrophages may degrade between 5 and 50% of disaturated-phosphatidylcholine, the rest being lost from tissue. In ARDS we assumed that 5-100% of disaturated-phosphatidylcholine is degraded in the alveolar space, due to release of hydrolytic enzymes. Some of the kinetic parameters were uniquely determined, while others were identified as lower and upper bounds. RESULTS: In ARDS, the alveolar pool of disaturated-phosphatidylcholine was significantly lower than in controls (0.16 +/- 0.04 vs. 1.31 +/- 0.40 mg/kg, p < 0.05). Fluxes between tissue and alveoli and de novo synthesis of disaturated-phosphatidylcholine were also significantly lower, while mean resident time in lung tissue was significantly higher in ARDS than in controls. Recycling was 16.2 +/- 3.5 in ARDS and 31.9 +/- 7.3 in controls (p = 0.08). CONCLUSION: In ARDS the alveolar pool of surfactant is reduced and disaturated-phosphatidylcholine turnover is altered.


Subject(s)
Lung/metabolism , Models, Biological , Pulmonary Alveoli/metabolism , Pulmonary Surfactants/chemistry , Pulmonary Surfactants/metabolism , Respiratory Distress Syndrome/metabolism , 1,2-Dipalmitoylphosphatidylcholine/administration & dosage , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Adult , Aged , Carbon Isotopes , Female , Humans , Instillation, Drug , Male , Middle Aged , Trachea
8.
J Colloid Interface Sci ; 295(1): 84-92, 2006 Mar 01.
Article in English | MEDLINE | ID: mdl-16115641

ABSTRACT

The competitive adsorption of fibrinogen (FB) and DPPC at the air/aqueous interface, in phosphate buffer saline at 25 degrees C, was studied with tensiometry, infrared reflection absorption spectroscopy (IRRAS), and ellipsometry. For FB/DPPC mixtures with 750 ppm (0.075 wt%) FB and 1000 ppm (0.10 wt%) DPPC, the tension behavior was found to be similar to that of FB when alone, even with DPPC and FB being at the interface. Thus, FB interferes with adsorption of DPPC and inhibits its surface tension lowering ability. When FB protein is introduced in the solution after a DPPC monolayer has formed, the adsorption of FB is inhibited by the DPPC monolayer. When a DPPC monolayer is spread onto a solution with a preadsorbed FB layer, the DPPC monolayer excludes FB from the surface and controls the tension behavior with little inhibition by FB. When a DPPC dispersion is introduced with the Trurnit method, or sprayed dropwise, onto an aqueous FB/DPPC surfaces, the DPPC layer formed on the surface prevents the adsorption of FB and dominates the surface tension behavior. These results have implications in controlling the inhibition of lung surfactant tension behavior by serum proteins, when they leak at the alveolar lining layer, and in developing surfactant replacement therapies for alveolar respiratory diseases.


Subject(s)
1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Air , Fibrinogen/pharmacokinetics , Water , Adsorption
9.
J Invest Dermatol ; 124(3): 622-32, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15737204

ABSTRACT

The feasibility of monitoring the permeation of chain perdeuterated 1,2-dipalmitoylphosphatidylcholine (DPPC-d62) and 1-palmitoyl-d31, 2-oleoylphosphatidylcholine (P-d31OPC) vesicles into pigskin using infrared (IR) microscopic imaging and confocal Raman microscopy was demonstrated. The former technique permits the examination of the relative concentration of molecular species (e.g., endogenous and exogenous lipids and proteins) over spatial areas, approximately 1 mm, with a spatial resolution of approximately 10-12 microm. In contrast, Raman microscopy allows the confocal examination of tissue at depths up to 100 microm with a pixel size of about 2-3 microm3. Spectral signal/noise, however, is reduced from IR and significantly smaller areas are generally monitored. The permeation of the gel phase DPPC-d62 was limited to approximately 5-15 microm, whereas the liquid-crystalline phase P-d31OPC permeated to substantially greater depths (35-100 microm), at times ranging up to 24 h after application. The results are generally in accord with literature values. In addition, the state of the P-d31OPC (intact vesicles or molecularly dispersed with skin constituents) was evaluated from the spatial dependence of the deuteriopalmitate chain conformational order. Upon permeation, the chains became more ordered. The advantages and limitations of these imaging technologies are discussed.


Subject(s)
Phospholipids/pharmacokinetics , Skin/metabolism , Spectrophotometry, Infrared/methods , Spectrum Analysis, Raman/methods , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Animals , Deuterium , Feasibility Studies , Liposomes/metabolism , Membrane Fluidity , Phosphatidylcholines/pharmacokinetics , Swine
10.
Int J Pharm ; 292(1-2): 179-85, 2005 Mar 23.
Article in English | MEDLINE | ID: mdl-15725564

ABSTRACT

An important step in liposome characterization is to determine the location of a drug within the liposome. This work thus investigated the interaction of dipalmitoylphosphatidylcholine liposomes with drugs of varied water solubility, polar surface area (PSA) and partition coefficient using high sensitivity differential scanning calorimetry. Lipophilic estradiol (ES) interacted strongest with the acyl chains of the lipid membrane, followed by the somewhat polar 5-fluorouracil (5-FU). Strongly hydrophilic mannitol (MAN) showed no evidence of interaction but water soluble polymers inulin (IN) and an antisense oligonucleotide (OLG), which have very high PSAs, interacted with the lipid head groups. Accordingly, the drugs could be classified as: hydrophilic ones situated in the aqueous core and which may interact with the head groups; those located at the water-bilayer interface with some degree of penetration into the lipid bilayer; those lipophilic drugs constrained within the bilayer.


Subject(s)
Drug Interactions , Liposomes/chemistry , Surface Properties/drug effects , 1,2-Dipalmitoylphosphatidylcholine/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Calorimetry, Differential Scanning/methods , Chemistry, Pharmaceutical , Drug Design , Estradiol/chemistry , Estradiol/pharmacokinetics , Fluorouracil/chemistry , Fluorouracil/pharmacokinetics , Hydrophobic and Hydrophilic Interactions , Inulin/chemistry , Inulin/pharmacokinetics , Liposomes/pharmacokinetics , Mannitol/chemistry , Mannitol/pharmacokinetics , Oligonucleotides, Antisense , Solubility , Water
11.
Pediatr Pulmonol ; 39(2): 167-77, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15633204

ABSTRACT

Surfaxin (lucinactant), a peptide-based surfactant consisting of dipalmitoylphosphatidylcholine (DPPC) plus KL(4) (sinapultide) (a synthetic peptide modeled after human surfactant protein-B), is effective in treating respiratory distress syndrome in preterm infants. Our goal was to determine the uptake and effects of Surfaxin on human pulmonary type II cells isolated from fetal tissue and other lung cell types. Based on previous published reports, we hypothesized that this exogenous synthetic surfactant would have little effect on type II cell surfactant-related physiological features. Human type II cells and A549 and NCI-H441 adenocarcinoma cells incorporated (3)H-KL(4) and (14)C-DPPC components in Surfaxin, but with different kinetics. Fractionation of NCI-H441 and A549 cellular components indicated that the highest specific activity of (3)H-KL(4) was present in the 18,000g cellular fraction (which contains vesicles and lysosomes). The number of lamellar bodies (LBs) appears to increase in human type II cells incubated in the presence of Surfaxin when visualized by light microscopy, while LB structure (determined by electron microscopy) was not altered. Expression of endogenous surfactant protein (SP-A, SP-B, and SP-C) mRNA levels in human type II cells was not altered by the presence of Surfaxin. We conclude that while human type II cells and other lung cell types can incorporate the components of Surfaxin, the surfactant-related physiological functions of these cells are not altered.


Subject(s)
1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Peptides/metabolism , Proteins/pharmacokinetics , Pulmonary Alveoli/embryology , Respiratory Mucosa/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Blotting, Northern , Brefeldin A/pharmacology , Cell Line, Tumor , Cells, Cultured , Culture Media, Serum-Free/chemistry , Drug Combinations , Exocytosis/drug effects , Exocytosis/physiology , Humans , In Vitro Techniques , Intercellular Signaling Peptides and Proteins , Intracellular Fluid/metabolism , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Microscopy, Electron , Organelles/drug effects , Organelles/ultrastructure , Peptides/drug effects , Peptides/genetics , Protein Synthesis Inhibitors/pharmacology , Pulmonary Alveoli/drug effects , Pulmonary Alveoli/metabolism , RNA, Messenger/genetics , Respiratory Mucosa/drug effects , Respiratory Mucosa/embryology
12.
J Matern Fetal Neonatal Med ; 16 Suppl 2: 21-4, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15590429

ABSTRACT

Deficiency or dysfunction of pulmonary surfactant plays a critical role in the pathogenesis of respiratory diseases in the newborn. We describe the studies made by applying two recently developed methods to measure surfactant kinetics. The first allows the measurement of endogenous surfactant phosphatidylcholine (PC) synthesis and kinetics by a constant intravenous infusion of glucose or fatty acids labeled with stable isotope 13C. The second method consists of endotracheal administration of a tracer dose of 13C-labeled dipalmitoyl-phosphatidylcholine (DPPC) to measure disaturated-phosphatidylcholine (DSPC) half-life and apparent pool size. We present the results of surfactant kinetics in some of the respiratory diseases of the newborn infant.


Subject(s)
1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Phosphatidylcholines/biosynthesis , Pulmonary Surfactants/pharmacokinetics , Respiratory Distress Syndrome, Newborn/drug therapy , 1,2-Dipalmitoylphosphatidylcholine/therapeutic use , Humans , Infant, Newborn , Infant, Newborn, Diseases/drug therapy , Pulmonary Surfactants/therapeutic use
13.
Yao Xue Xue Bao ; 39(7): 551-5, 2004 Jul.
Article in Chinese | MEDLINE | ID: mdl-15493849

ABSTRACT

AIM: To investigate the biodistribution and the hepatocytes targeting of cationic liposome containing 3beta[N-( N',N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) and surface-modified liposomes with sterylglucoside (SG) and polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE). METHODS: Cationic liposomes (CL) composed of DC-Chol and dipalmitoylphosphatidylcholine (DPPC), SG/PEG modified cationic liposome (SG/PEG-CL), both contained trace 3H-cholesterol (3H-Chol) as radiolabel, were prepared. The liposomes encapsulating 125I-labled antisense oligodeoxynucleotide (125I-asODN) (SG/PEG-CL-asODN) were also prepared. The biodistribution of CL, SG/PEG-CL, SG/PEG-C2-asODN as well as 125I-asODN solution, were studied. The radioactivities in hepatocytes and non-hepatocytes after administration of CL and SG/PEG-CL were determined by infuseing method. RESULTS: CL and SG/PEG CL significantly aggregated in liver. The distribution of SG/PEG CL was significantly higher in hepatocytes (P < 0.01) and lower in non-hepatocytes (P < 0.01) than that of CL. The concentrations of SG/PEG-CL-asODN in liver and spleen were significantly higher than that of asODN solution (P < 0.01). CONCLUSION: Cationic liposome modified with SG/PEG changed the distribution of asODN. Cationic liposome can target hepatocytes more effective after being modified with SG.


Subject(s)
Cholestenes/pharmacokinetics , Cholesterol/analogs & derivatives , Hepatocytes/metabolism , Liposomes/pharmacokinetics , 1,2-Dipalmitoylphosphatidylcholine/administration & dosage , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Animals , Area Under Curve , Cholestenes/administration & dosage , Cholesterol/administration & dosage , Cholesterol/pharmacokinetics , Drug Carriers , Drug Delivery Systems , Liposomes/administration & dosage , Male , Mice , Oligodeoxyribonucleotides, Antisense/administration & dosage , Oligodeoxyribonucleotides, Antisense/pharmacokinetics , Phosphatidylethanolamines/administration & dosage , Phosphatidylethanolamines/pharmacokinetics , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/pharmacokinetics , Tissue Distribution
14.
Drug Deliv ; 11(1): 33-9, 2004.
Article in English | MEDLINE | ID: mdl-15168789

ABSTRACT

Liposomes are colloidal carriers that form when certain (phospho)lipid molecules are hydrated in an aqueous media with some energy input. The ideal liposome formulation with optimum stability will improve drug delivery by decreasing the required dose and increasing the efficacy of the entrapped drug at the target organ or tissue. The most important parameter of interest in this article was to compare the efficacy of three different liposomes formulated with DSPC, DMPC, and DPPC, all saturated neutral phospholipids with different acyl chain lengths and transition temperatures. DMPC has a phase transition temperature (Tc) below 37 degrees C, whereas the other two phospholipids possess Tcs above the physiological temperature. These lipids were then added to a cholesterol concentration of 21% to optimize the stability of the vesicles. The liposomes were prepared by a sonication and incubated in phosphate buffered saline (PBS) at 4 degrees C and 37 degrees C. The encapsulation efficiency, initial size, and drug retention of the vesicles were tested over a 48-hr period employing radiolabeled inulin as a model drug. The phase transition temperature of liposomes, which depends on the Tc of the constituent lipids, was an important factor in liposome stability. Of all the liposomes tested, the greatest encapsulation efficiency was found for the DSPC liposomes (2.95%) that also had the greatest drug retention over 48 hr at both 4 degrees C (87.1 +/- 6.8%) and 37 degrees C (85.2 +/- 10.1%), none of these values being significantly different from time zero. The lowest drug retention was found for DMPC liposomes for which a significant difference in drug retention was seen after only 15 min at both 4 degrees C (47.3 +/- 6.9%) and 37 degrees C (53.8 +/- 4.3%). The DPPC liposomes showed a significant difference in drug retention after 3 hr at 4 degrees C (62.1 +/- 8.2%) and after 24 hr at 37 degrees C (60.8 +/- 8.9%). Following the initial drop at certain time intervals a plateau was reached for all of the liposome formulations after which no significant difference in drug retention was observed. In conclusion, liposomes with higher transition temperatures appear to be more stable in PBS either at 4 degrees C or 37 degrees C, indicating that the increase in acyl chain length (and therefore transition temperature) is directly proportional to stability.


Subject(s)
Chemistry, Pharmaceutical/methods , Drug Stability , Liposomes/chemistry , Liposomes/pharmacokinetics , 1,2-Dipalmitoylphosphatidylcholine/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Acylation , Buffers , Carbon Radioisotopes/pharmacokinetics , Cholesterol/chemistry , Dimyristoylphosphatidylcholine/chemistry , Dimyristoylphosphatidylcholine/pharmacokinetics , Drug Compounding/methods , Inulin/chemistry , Inulin/pharmacokinetics , Liposomes/chemical synthesis , Phosphates/chemistry , Phosphates/pharmacokinetics , Phosphatidylcholines/chemistry , Phosphatidylcholines/pharmacokinetics , Sodium Chloride/chemistry , Sodium Chloride/pharmacokinetics , Solutions , Temperature , Time Factors , Ultrasonics
15.
J Pharm Sci ; 93(1): 86-98, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14648639

ABSTRACT

Molecular interactions between paclitaxel and dipalmitoylphosphatidyl choline (DPPC) were investigated by Langmuir film balance and differential scanning calorimetry (DSC). Both the lipid monolayer at the air-water interface and that in the lipid bilayer vesicles (liposomes) were employed as model cell membranes. Thermodynamic and kinetic analyses of the DPPC/pacltaxel monolayer system and the paclitaxel penetration into the DPPC monolayer showed that DPPC and paclitaxel can form a nonideal miscible system in the lipid monolayer over a wide range of the DPPC/paclitaxel molar ratios. Paclitaxel exerts an area-condensing effect on the DPPC monolayer at small molecular areas and an area-expanding effect at large molecular areas on the pi-A behavior of the DPPC monolayer, which can be explained by the intermolecular forces and geometric accommodation between paclitaxel and DPPC. Based on a calculation of the excess free energy of the mixed monolayer system, the most stable state of the system occurs at the monolayer composition of 5% paclitaxel. Penetration kinetics showed that the paclitaxel penetration into the DPPC monolayer increases with increasing the drug concentration in the subphase, but there is a limit of approximately 500 ng/mL. Any further increase in paclitaxel concentration had no additional significant effects on the drug penetration. Differential scanning calorimetry showed that paclitaxel caused broadening of the main phase transition. There was no significant change in the peak melting temperature of the DPPC bilayers, which demonstrated that paclitaxel was localized in the outer hydrophobic cooperative zone of the bilayer.


Subject(s)
1,2-Dipalmitoylphosphatidylcholine/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Paclitaxel/chemistry , Paclitaxel/pharmacokinetics , Calorimetry, Differential Scanning/methods , Drug Interactions/physiology , Molecular Structure , Surface Properties/drug effects
16.
J Photochem Photobiol B ; 72(1-3): 1-9, 2003 Dec 05.
Article in English | MEDLINE | ID: mdl-14644560

ABSTRACT

Two-component monomolecular layers were formed with DPPC and two stereoisomers of zeaxanthin 9-cis and 13-cis at the argon-water interface. Very distinct over-additivity which represents affection of a lipid arrangement in the membrane has been observed in the case of zeaxanthin 9-cis (maximum at 20 mol%) but not in the case of zeaxanthin 13-cis. The differences in the organization of the isomers of zeaxanthin-DPPC monolayers are interpreted in terms of the different orientation of both xanthophylls at the interface observed at relatively high surface pressures (>25 mN/m) comparable to the surface pressures of biomembranes. The results are consistent with the model according to which zeaxanthin 9-cis adopts a vertical orientation at the polar-nonpolar interface in contrast to zeaxanthin 13-cis, which is oriented horizontally owing to the fact that it interacts by two hydroxyl groups with the same hydrophobic-hydrophilic interface in the monolayer. The findings are discussed in comparison with the behavior of zeaxanthin in the conformation all-trans in the same system. Zeaxanthin all-trans forms efficiently molecular aggregates in the mixed monolayers in contrast to cis isomers. Circular dichroism measurements show the formation of molecular structures by zeaxanthin 13-cis that are interpreted as dimers. FTIR measurements show that these dimers are stabilized by van der Waals interactions unlike aggregated structures formed by all-trans zeaxanthin that are stabilized by hydrogen bonding. Physiological importance of the differences in aggregation and orientation of stereoisomers of zeaxanthin in lipid environment is discussed.


Subject(s)
1,2-Dipalmitoylphosphatidylcholine/chemistry , Membranes, Artificial , Xanthophylls/chemistry , beta Carotene/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Stereoisomerism , Xanthophylls/pharmacokinetics , Zeaxanthins , beta Carotene/analogs & derivatives , beta Carotene/pharmacokinetics
17.
Bioconjug Chem ; 14(6): 1156-64, 2003.
Article in English | MEDLINE | ID: mdl-14624629

ABSTRACT

The objective of this study was to develop biodegradable polypeptide-lipid conjugates for the design of polymer-coated long-circulating liposomes (LCL). Lipid conjugates of poly(hydroxyalkyl L-asparagine/L-glutamine) were synthesized and incorporated into 0.15 microm dipalmitoyl phosphatidylcholine (DPPC)-cholesterol liposomes. Circulation times and biodistribution were assessed in rats using a radioactive lipid marker. Evaluation of the therapeutic activity of prednisolone phosphate loaded in 0.1 microm PHEA-DPPC-cholesterol liposomes in a rat experimental arthritis model was performed to demonstrate the drug-targeting potential of the polymer-coated liposomes. Coating of liposomes with poly(hydroxyethyl L-asparagine) (PHEA) and poly(hydroxyethyl L-glutamine) (PHEG) extended the circulation half-life to a similar extent as poly(ethylene glycol) (PEG), which is normally used for the preparation of LCL. Glutamine polymers with a hydroxypropyl or a hydroxybutyl group instead of hydroxyethyl group also yield prolonged circulation, however, not to the same extent as PHEA/G. The pharmacokinetic properties of PHEA-liposomes were independent of the lipid dose even at very low lipid doses of around 50 nmol per rat. PLP was successfully entrapped in PHEA-liposomes. These liposomes were shown to be stable in the circulation and equally effective in rat experimental arthritis as PLP encapsulated in PEG-liposomes. PHEA and PHEG are attractive alternative polymers for the design of LCL: their performance is similar to that of PEG-liposomes but they have the advantage of being biodegradable.


Subject(s)
Amino Acids/chemistry , Drug Delivery Systems , Lipids/chemistry , Liposomes/chemistry , Polymers/chemistry , 1,2-Dipalmitoylphosphatidylcholine/chemistry , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Amino Acids/chemical synthesis , Animals , Anti-Inflammatory Agents/pharmacokinetics , Arthritis, Experimental/drug therapy , Biodegradation, Environmental , Half-Life , Liposomes/metabolism , Liposomes/pharmacokinetics , Male , Molecular Structure , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Polymers/chemical synthesis , Rats , Rats, Inbred Lew , Rats, Wistar , Tissue Distribution
18.
J Asthma ; 40(4): 445-50, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12870840

ABSTRACT

BACKGROUND: In a recent study in animals it has been shown how surface-active phospholipid (SAPL) in the form of a commercially available micronized (5 micromphi) dry powder (ALECT/PumactantT) was able to reduce afferent neural feedback to the brainstem in response to a methacholine challenge by the same order of magnitude as drugs commonly prescribed for asthma. The underlying theory assumed that adsorption of SAPL to bronchial epithelium masked irritant receptors eliciting the bronchoconstrictor reflex, thus providing a barrier to noxious stimuli entering the lungs. OBJECTIVE: To test the underlying assumption that SAPL was actually adsorbed (i.e., bound to bronchial epithelium), especially the major and most surface-active component of lung surfactant, namely dipalmitoyl phosphatidylcholine (DPPC). A secondary objective was to investigate any role of phosphatidylglycerol (PG) in promoting the adsorption of DPPC. METHODS: Radiolabeled DPPC dispersed ultrasonically in saline was used to incubate excised sections of porcine bronchial epithelium. The adsorbed DPPC was then quantified by rigorously rinsing the tissue of adhering fluid and then digesting it for beta-scintillation counting. Each test (n=8 runs) was repeated for ratios of DPPC:PG of 9:1, 7:3 (as per ALECT/PumactantT) and 1:1 for both dipalmitoyl PG (DPPG) and EggPG (as incorporated in ALECT/PumactantT). RESULTS: Despite rigorous rinsing postincubation, bronchial epithelium was found to adsorb DPPC at a level roughly equivalent to one close-packed monolayer; whereas both DPPG and EggPG promoted the adsorption of DPPC in a dose-dependent manner, reaching an approximate threefold increase for 7:3 DPPC:PG. CONCLUSION: DPPC adsorbs to bronchial epithelium in amounts necessary for the masking of receptors, and this adsorption (probably chemisorption) is quite strongly promoted by PG either in its indigenous state (DPPG) or in the form (EggPG) used in ALECT to suppress the sensitivity of bronchial irritant receptors in our previous study and in clinical trials just completed.


Subject(s)
1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Phosphatidylglycerols/pharmacokinetics , Pulmonary Surfactants/pharmacokinetics , Receptors, Cell Surface/metabolism , Respiratory Mucosa/metabolism , Animals , Bronchi , In Vitro Techniques , Models, Animal , Swine
19.
Crit Care Med ; 31(5): 1532-8, 2003 May.
Article in English | MEDLINE | ID: mdl-12771629

ABSTRACT

OBJECTIVE: To characterize surfactant kinetics in vivo in two groups of premature infants on different levels of mechanical ventilation and at different risk of developing bronchopulmonary dysplasia. DESIGN: Controlled observational study in two independent groups of infants. SETTING: Neonatal intensive care unit. PATIENTS: Thirteen preterm infants (26 +/- 0.5 wks, birth weight 801 +/- 64 g) on high ventilatory setting and who finally all developed bronchopulmonary dysplasia (MechVentBPD), and eight (26 +/- 0.5 wks, birth weight 887 +/- 103 g) who had minimal or no lung disease and of whom none developed bronchopulmonary dysplasia (MechVentNoBPD). MEASUREMENTS AND MAIN RESULTS: Endotracheal 13C-labeled dipalmitoyl-phosphatidylcholine was administered and subsequent measurements of the 13C enrichment of surfactant-disaturated phosphatidylcholine (DSPC) from serial tracheal aspirates were made by gas chromatography-mass spectrometry. We calculated disaturated phosphatidylcholine pharmacokinetic variables in terms of half-life and apparent pool size from the enrichment decay curves over time. DSPC concentration from tracheal aspirates was expressed as milligrams/milliliter epithelial lining fluid (ELF-DSPC). Data are presented as mean +/- se. In MechVentBPD infants vs. MechVentNoBPD, ELF-DSPC was much reduced, 2.9 +/- 0.6 vs. 9.4 +/- 3.0 mg/mL ELF (p =.03), half-life was shorter, 19.4 +/- 2.8 vs. 42.5 +/- 6.3 hrs (p =.002), and apparent pool size larger, 136 +/- 21 vs. 65.8 +/- 16.0 mg/kg (p =.057). In MechVentBPD, apparent DSPC pool size positively correlated with mean airway pressure x Fio(2) and inversely correlated with ELF-DSPC. ELF-DSPC was inversely correlated with mean airway pressure x Fio(2). No significant correlations were found in the MechVentNoBPD group. CONCLUSIONS: MechVentBPD infants showed profound alteration of surfactant kinetics compared with preterm infants with minimal lung disease, and these alterations were correlated with severity of ventilatory support.


Subject(s)
Bronchopulmonary Dysplasia/etiology , Bronchopulmonary Dysplasia/metabolism , Pulmonary Surfactants/metabolism , Respiration, Artificial/adverse effects , 1,2-Dipalmitoylphosphatidylcholine/administration & dosage , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , Airway Resistance , Birth Weight , Bronchopulmonary Dysplasia/classification , Bronchopulmonary Dysplasia/physiopathology , Carbon Isotopes/analysis , Carbon Isotopes/pharmacokinetics , Case-Control Studies , Gas Chromatography-Mass Spectrometry , Gestational Age , Half-Life , Humans , Infant, Newborn , Instillation, Drug , Phosphatidylcholines/analysis , Pressure , Regression Analysis , Risk Factors , Severity of Illness Index , Sputum/chemistry , Time Factors
20.
Am J Physiol Lung Cell Mol Physiol ; 284(5): L759-65, 2003 May.
Article in English | MEDLINE | ID: mdl-12676766

ABSTRACT

The role of surfactant protein-A (SP-A) in pulmonary uptake and metabolism of [(3)H]dipalmitoylphosphatidylcholine ([(3)H]DPPC) was studied in SP-A gene-targeted mice (SP-A -/-). Unilamellar liposomes were instilled into the trachea of anesthetized mice. Uptake was measured as dpm in lungs plus liver and kidney for in vivo experiments and in lungs and perfusate for isolated lung experiments. [(3)H]DPPC uptake increased with CO(2)-induced hyperventilation in wild-type mice (SP-A +/+) but was unchanged in SP-A -/-. Secretagogue treatment approximately doubled the uptake of [(3)H]DPPC in isolated lungs from SP-A +/+ but had no effect in SP-A -/-. Lungs degraded 23 +/- 1.2% of internalized [(3)H]DPPC in SP-A +/+ and 36 +/- 0.6% in SP-A -/-; degradation increased with 8-bromoadenosine 3',5'-cyclic monophosphate in SP-A +/+ but was unchanged in SP-A -/-. Activity of lysosomal-type phospholipase A(2) (PLA(2)) was significantly greater in lungs from SP-A -/- compared with SP-A +/+. Thus SP-A is necessary for lungs to respond to hyperventilation or secretagogues with increased DPPC uptake and also modulates the PLA(2)-mediated degradation of internalized DPPC.


Subject(s)
Hyperventilation/metabolism , Pulmonary Alveoli/metabolism , Pulmonary Surfactant-Associated Protein A/genetics , Pulmonary Surfactant-Associated Protein A/metabolism , 1,2-Dipalmitoylphosphatidylcholine/pharmacokinetics , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Animals , Disease Models, Animal , Endocytosis/physiology , Lysosomes/enzymology , Mice , Mice, Knockout , Phospholipases A/metabolism , Pulmonary Alveoli/drug effects , Stem Cells/physiology , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...